🇺🇸 FDA
Patent

US 10654916

Compositions and methods for the treatment of neuromyelitis optica

granted A61KA61K39/3955A61K45/06

Quick answer

US patent 10654916 (Compositions and methods for the treatment of neuromyelitis optica) held by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION
Grant date
Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K39/3955, A61K45/06, A61P, A61P1/08